|
1
|
Besbes S, Mirshahi M, Pocard M and Billard
C: Strategies targeting apoptosis proteins to improve therapy of
chronic lymphocytic leukemia. Blood Rev. 29:345–350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cramer P, Eichhorst B, Reinhardt HC and
Hallek M: Current strategies to create tailored and risk-adapted
therapies for CLL patients. Best Pract Res Clin Haematol.
29:111–121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Visentin A, Facco M, Frezzato F, Castelli
M, Trimarco V, Martini V, Gattazzo C, Severin F, Chiodin G,
Martines A, et al: Integrated CLL scoring system, a new and simple
index to predict time to treatment and overall survival in patients
with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk.
15:612–620.e1-5. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koffman B and Schorr A: The 21st century
revolution in CLL: Why this matters to patients. Best Pract Res
Clin Haematol. 29:122–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klein U and Dalla-Favera R: Germinal
centres: Role in B-cell physiology and malignancy. Nat Rev Immunol.
8:22–33. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hallek M: Chronic lymphocytic leukemia:
2013 update on diagnosis, risk stratification and treatment. Am J
Hematol. 88:803–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin-Subero JI, López-Otín C and Campo
E: Genetic and epigenetic basis of chronic lymphocytic leukemia.
Curr Opin Hematol. 20:362–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rogalińska M, Franiak-Pietryga I, Błoński
JZ, Góralski P, Maciejewski H, Janus A, Robak P, Mirowski M,
Piekarski H, Robak T and Kiliańska ZM: Toward personalized therapy
for chronic lymphocytic leukemia: DSC and cDNA microarray
assessment of two cases. Cancer Biol Ther. 14:6–12. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodriquez-Vicente AE, Díaz MG and
Hernández-Rivas JM: Chronic lymphocytic leukemia: A clinical and
molecular heterogenous disease. Cancer Genet. 206:49–62. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rogalinska M, Goralski P, Wozniak K,
Bednarek JD, Blonski JZ, Robak T, Piekarski H, Hanausek M, Walaszek
Z and Kilianska ZM: Calorimetric study as a potential test for
choosing treatment of B-cell chronic lymphocytic leukemia. Leuk
Res. 33:308–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jeyakumar D and O'Brien S: B cell receptor
inhibition as a target for CLL therapy. Best Pract Res Clin
Haematol. 29:2–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferrajoli A, Shanafelt TD, Ivan C, Shimizu
M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, et
al: Prognostic value of miR-155 in individuals with monoclonal
B-cell lymphocytosis and patients with B chronic lymphocytic
leukemia. Blood. 122:1891–1899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rogalińska M and Kiliańska ZM:
Personalised therapy versus targeted therapy, differences in
meaning. Glo J Res Anal. 4:5–8. 2015.
|
|
14
|
Rogalińska M, Błoński JZ, Góralski P,
Wawrzyniak E, Hartman M, Rogalska A, Robak P, Koceva-Chyła A,
Piekarski H, Robak T and Kiliańska ZM: Relationship between in
vitro drug sensitivity and clinical response of patients to
treatment in chronic lymphocytic leukemia. Int J Oncol.
46:1259–1267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rogalińska M, Góralski P, Błoński JZ,
Robak P, Barciszewski J, Koceva-Chyła A, Piekarski H, Robak T and
Kilianska ZM: Personalized therapy tests for the monitoring of
chronic lymphocytic leukemia development. Oncol Let. 13:2079–2084.
2017. View Article : Google Scholar
|
|
16
|
Montserrat E, Bauman T and Delgado J:
Present and future of personalized medicine in CLL. Best Pract Res
Clin Haematol. 29:100–110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piggin A, Bayly E and Tam CS: Novel agents
versus chemotherapy as frontline treatment of CLL. Leuk Lymph.
58:1320–1324. 2017. View Article : Google Scholar
|
|
18
|
Rogalińska M and Kiliańska ZM: Potential
new agents for chronic lymphocytic leukemia treatment. Anticancer
Agents Med Chem. 10:666–682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robak T, Stilgenbauer S and Tedeschi A:
Front-line treatment of CLL in the era of novel agents. Cancer
Treat Rev. 53:70–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hallek M: Role and timing of new drugs in
CLL. Hematol Oncol. 35 (Suppl 1):S30–S32. 2017. View Article : Google Scholar
|
|
21
|
Whittaker S, Mallinger A, Workman P and
Clarke PA: Inhibitors of cyclin-dependent kinases as cancer
therapeutics. Pharmacol Ther. 173:83–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niesvizky R, Badros AZ, Costa LJ, Ely SA,
Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch
S, et al: Phase 1/2 study of cyclin-dependent kinase (CDK)4/6
inhibitor palbociclib (PD-0332991) with bortezomib and
dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymph.
56:3320–3328. 2015. View Article : Google Scholar
|
|
23
|
Edessa D and Sisay M: Recent advances of
cyclin-dependent kinases as potential therapeutic targets in
HR+/HER2-metastatic breast cancer: A focus on ribociclib. Breast
Cancer (Dove Med Press). 9:567–579. 2017.PubMed/NCBI
|
|
24
|
Blachly JS, Byrd JC and Grever M:
Cyclin-dependent kinase inhibitors for the treatment of chronic
lymphocytic leukemia. Semin Oncol. 43:265–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, Germano S, Clements C, Samuel J,
Shelmani G, Jayne S, Dryer MJ and Macip S: Pro-survival signal
inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic
Leukaemia. Br J Haematol. 175:641–651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gucký T, Jorda R, Zatloukal M, Bazgier V,
Berka K, Řezníčková E, Béres T, Strnad M and Kryštof V: A novel
series of highly potent 2,6,9-trisubstituted purine
cyclin-dependent kinase inhibitors. J Med Chem. 56:6234–6247. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haider C, Grubinger M, Řezníčková E, Weiss
TS, Rotheneder H, Miklos W, Berger W, Jorda R, Zatloukal M, Gucky
T, et al: Novel inhibitors of cyclin-dependent kinases combat
hepatocellular carcinoma without inducing chemoresistance. Mol
Cancer Ther. 12:1947–1957. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Allegri L, Baldan F, Mio C, Puppin C,
Russo D, Kryštof V and Damante G: Effects of BP-14, a novel
cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer
cells. Oncol Rep. 35:2413–2418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rodriguez D, Bretones G, Arango JR,
Valdespino V, Campo E, Quesada V and López-Otín C: Molecular
pathogenesis of CLL and its evolution. Int J Hematol. 101:219–228.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tong WG, Chen R, Plunkett W, Siegel D,
Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, et
al: Phase I and pharmacologic study of SNS-032, a potent and
selective Cdk2, 7, and 9 inhibitor, in patients with advanced
chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol.
28:3015–3022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ge Y, Lei W, Ma Y, Wang Y, Wei B, Chen X,
Ru G, He X, Mou X and Wang S: Synergistic antitumor effects of CDK
inhibitor SNS-032 and an oncolytic adenovirus co-expressing TRAIL
and Smac in pancreatic cancer. Mol Med Rep. 15:3521–3528. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Flynn J, Jones J, Johnson AJ, Andritsos L,
Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, et al:
Dinaciclib is a novel cyclin-dependent kinase inhibitor with
significant clinical activity in relapsed and refractory chronic
lymphocytic leukemia. Leukemia. 29:1524–1529. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Robak P and Robak T: Novel synthetic drugs
currently in clinical development for chronic lymphocytic leukemia.
Expert Opin Investig Drugs. 26:1249–1265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Awan FT, Kay NE, Davis ME, Wu W, Geyer SM,
Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, et al: Mcl-1
expression predicts progression-free survival in chronic
lymphocytic leukemia patients treated with pentostatin,
cyclophosphamide, and rituximab. Blood. 113:535–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kozako T, Suzuki T, Yoshimitsu M, Arima N,
Honda S and Soeda S: Anticancer agents targeted to sirtuins.
Molecules. 19:20295–20313. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Albayrak A, Halici Z, Cadirci E, Polat B,
Karakus E, Bayir Y, Unal D, Atasoy M and Dogrul A: Inflammation and
peripheral 5-HT7 receptors: The role of 5-HT7 receptors in
carrageenan induced inflammation in rats. Eur J Pharmacol.
715:270–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Polat B, Halici Z, Cadirci E, Albayrak A,
Karakus E, Bayir Y, Bilen H, Sahin A and Yuksel TN: The effect of
alpha-lipoic acid in ovariectomy and inflammation-mediated
osteoporosis on the skeletal status of rat bone. Eur J Pharmacol.
718:469–474. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rogalinska M: The role of mitochondria in
cancer induction, progression and changes in metabolism. Mini Rev
Med Chem. 16:524–530. 2016. View Article : Google Scholar : PubMed/NCBI
|
